Drug intelligence / Profile preview

GT-02624

Lead developer
Gluetacs Therapeutics
01

Overview

Based on this platform, we developed: (1) GT-02624, a GSPT1 molecular glue degrader with small size, degradation selectivity among the tested canonical CRBN neosubstrates and corresponding anti-proliferative activity; and (2) GT-01956, a BET-targeting PROTAC exhibiting picomolar degradation potency and exceptional anti-proliferative activity across hematologic and solid tumor cell lines.

02

Targets

03

Identity

04

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

05

Companies

06

Competitive landscape

Drugs on the same target
5

Most advanced

  1. MRT-2359Phase 2
  2. CG009301Phase 1
  3. CT-01Phase 1
  4. FD-001Phase 1
  5. ORM-1153Phase 1

Beyond the preview

Go deeper on GT-02624.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT-02624.

Work on GT-02624? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call